Promedior is a clinical-stage biotechnology company developing a pipeline of novel Pentraxin-2 therapeutics for the treatment of fibrovascular diseases. Pentraxin-2 therapeutics treat fibrovascular diseases by naturally regulating monocyte-derived cells (macrophages and fibrocytes) that control the fibrotic process and drive pathologic neovascularization. Based on a unique mechanism of action, Pentraxin-2 localizes to sites of tissue damage and stimulates monocytes to differentiate into regulatory macrophages rather than pro-fibrotic macrophages and fibrocytes, thereby reversing inflammatory, fibrotic and neovascular processes and promoting normal healing. By acting upstream of these pathologic processes using a natural regulatory pathway, Pentraxin-2 therapeutics provide a superior therapeutic approach and an inherently safer profile.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/08/12 | $21,500,000 | Series D |
Easton Capital Fibrotec Ventures Forbion Capital Partners Healthcare Ventures Polaris Partners | undisclosed |
| 10/15/12 | $24,500,000 | Series D |
Easton Capital Fibrotec Ventures Forbion Capital Partners Healthcare Ventures Polaris Partners Shire Strategic Investment Group | undisclosed |
